| Topic: | diabetes (dm) |
| Title: | Exhuberance Over Exubera. |
| Author: | Hite, P.F.; Barnes, A.M.; Johnston, P.E. |
| Source: | Clinical Diabetes. 24(3): 110-114. Summer 2006. |
| Abstract: | This article reviews the history of the development of insulin used to treat diabetes, culminating in the newest entry in the insulin world, inhaled insulin (brand name Exubera). Exubera is recombinant-engineered human insulin that is delivered to the bloodstream via the lung's alveoli; approximately one-third of the administered dose is absorbed into the bloodstream. The onset of inhaled insulin acts as quickly as subcutaneously administered rapid-acting insulin and more quickly than subcutaneous regular insulin. The authors review the effectiveness of inhaled insulin, initiating inhaled insulin, tools for patients starting inhaled insulin, monitoring guidelines, and candidates for inhaled insulin use. The authors conclude that clinical data have shown increased patient acceptability with inhaled insulin compared to injectable insulin. More patients using insulin who need it results in better glycemic control, thereby reducing microvascular and macrovascular complications and leading to improved quality of life. Thus, although there are safety and cost considerations, inhaled insulin also offers potential adherence and satisfaction advantages. 4 tables. 22 references. |
| Format: | Journal Article |
| Language: | English. |
| Major Keywords: | Diabetes Mellitus. Inhaled Insulin. Drug Therapy. Drug Effects. Patient Selection. |
| Minor Keywords: | Monitoring. Patient Care Management. Type 2 Diabetes. Blood Glucose. Complications. Prevention. Patient Compliance. Costs. |
| Publication Number: | DMJA12813. |
| Return to Search Results | |